# Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Study · id `cardio:ct-nct05966272` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05966272](<https://clinicaltrials.gov/study/NCT05966272>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05966272

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.

## Technical summary

Registry record NCT05966272. Randomized; triple masking; primary purpose treatment. Start 2023-08-12 (actual); primary completion 2024-09-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 199 participants (enrolled count; ClinicalTrials.gov record NCT05966272, source copy `cardio:ctgov-nct05966272-2025-05-07`, retrieved 2026-10-26)
- Started: 2023-08-12 (actual) (ClinicalTrials.gov record NCT05966272, source copy `cardio:ctgov-nct05966272-2025-05-07`, retrieved 2026-10-26)
- Primary completion: 2024-09-24 (actual) (ClinicalTrials.gov record NCT05966272, source copy `cardio:ctgov-nct05966272-2025-05-07`, retrieved 2026-10-26)
- Completion: 2024-09-24 (actual) (ClinicalTrials.gov record NCT05966272, source copy `cardio:ctgov-nct05966272-2025-05-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05966272, source copy `cardio:ctgov-nct05966272-2025-05-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05966272-2025-05-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
- Condition: Type 2 Diabetes
- Intervention (Drug): HRS9531 injection
- Intervention (Drug): HRS9531 injection Placebo
- Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. (`cardio:org-fujian-shengdi-pharmaceutical-co-ltd`)

## Provenance

Content hash: 068fa1af287b0c7a6e7f8e254c1cdd5dbac328c0cc76d84bb2371d1a86e65991
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
